Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7677988 | 0.92 | PTGS2 (0.42) | PTGS2ABCB11SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7678256 | 0.90 | PTGS2 (0.46) | PTGS2ABCB11SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11716278 | 0.88 | PTGS2 (0.45) | PTGS2ABCB11SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7685136 | 0.87 | PTGS2 (0.53) | PTGS2ABCB11SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL10879290 | 0.87 | PTGS2 (0.44) | PTGS2ABCB11SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7683947 | 0.85 | PTGS2 (0.50) | PTGS2ABCB11SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11181072 | 0.85 | PTGS2 (0.42) | PTGS2ABCB11SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7682322 | 0.83 | THRB (0.48) | PTGS2ABCB11SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL10880007 | 0.83 | PTGS2 (0.44) | PTGS2ABCB11SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL11713532 | 0.81 | PTGS2 (0.42) | PTGS2ABCB11SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455703-B2 | ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION | CELL PATHWAYS, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | OSI PHARMACEUTICALS, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6160003-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-5939417-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS INC (US) | 1999-08-17 | — | — | US | disclosed |
| US-5721347-A | Esters and amides of substituted pyrrole acetic acids | CELL PATHWAYS, INC. (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0485157-A2 | Esters and amides of substituted pyrrole acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| US-4070368-A | ACYLATION, DECARBOXYLATION | MCNEIL LABORATORIES, INCORPORATED (US) | 1978-01-24 | — | — | US | disclosed |
| US-3952012-A | MULTISTAGE | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | MALT1, VHL, CDKN1A | PTGS2 887/4885ABCB11 2317/4885SMN1; SMN2 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.